What's happening in biotech?

Read time: 3 minutes

Welcome to the Succession newsletter where 550+ life science sales reps improve their skills in 5 minutes per week. If you’re getting value from these newsletters, we'd love it if you could forward it along to your sales colleagues. If you’re new here, subscribe below.

Shout out to Brian Schneider for the inspiration for today’s newsletter!

Many of the leaders and reps I’ve spoken with recently have mentioned how soft the market is right now. We’ve talked about it in our newsletters and shared data from polls and surveys as well.

It’s hard to be in sales in right now especially if you’re not selling a mission-critical product or service.

I analyzed the top tools and service companies and looked through their quarterly and annual announcements to get an idea of what the heck is going on.

Thanks to our good friend ChatGPT, I was able to pull out the key trends and approaches these companies are taking to counteract the current market.

Then we wrap it up with 5 strategies you can use a sales rep to improve your chances of success.

Let’s dive in!

Overview

The biotech industry, traditionally known for its rapid innovation and high demand for research tools and services, is currently navigating a period of contraction. Reduced spending by biotech and pharmaceutical companies, coupled with pipeline consolidation, has led to significant changes in market dynamics. Companies selling instruments, products, and services are experiencing ripple effects, from weaker revenue growth to increased competition and pricing pressures. This report explores key industry trends, challenges, and strategic responses based on recent developments across the sector.

1. Industry-wide Slowdown in Demand

Reduced Spending: Many biotech and pharmaceutical companies are cutting budgets, delaying projects, or prioritizing late-stage pipeline assets over earlier exploratory projects.

Impact on Revenue Streams: Companies selling instruments, consumables, and services are experiencing weaker demand, especially in R&D-heavy segments like early-stage drug discovery and genomic research.

2. Consolidation of Pipelines

Fewer New Projects: Pharma and biotech are consolidating pipelines, focusing resources on fewer programs with higher probabilities of success. This results in lower demand for experimental tools and services.

Shift in Customer Priorities: Companies are increasingly prioritizing products or services that align with clinical and regulatory success, particularly in high-demand areas like oncology, diagnostics, and personalized medicine.

3. Financial Pressures on Smaller Biotechs

Funding Challenges: Smaller biotechs, many of which were well-funded during the pandemic, now face significant financial strain due to higher interest rates and tighter capital markets.

High Cancellation Rates: Service providers like Charles River and Medpace report elevated cancellation rates as smaller biotechs run out of funding mid-project.

Strategic Shifts: Some providers are realigning their offerings to support large pharma clients, who remain more financially stable.

4. Focus on Efficiency and Cost Control

Cost Sensitivity: Customers are scrutinizing costs more closely, favoring products and services that offer clear ROI or enable automation and efficiency.

Operational Adjustments: Providers like QIAGEN and Danaher are expanding AI-driven tools, automation, and digitization to deliver cost-effective, scalable solutions.

5. Resilience in Diagnostics and Clinical Markets

Steady Growth in Diagnostics: Companies like Abbott and Bio-Rad see strong demand for diagnostic tools, as these are directly tied to clinical and patient outcomes.

Shift Toward Clinical Applications: Vendors are shifting focus from pure research tools to clinical diagnostic solutions, addressing more immediate market needs and revenue opportunities.

6. Increasing Competition and Pricing Pressure

Emerging Players: New competitors in key markets, such as genome sequencing, are driving pricing pressure and challenging established companies like Illumina.

Demand for Innovation: Customers are seeking differentiated products, such as digital PCR (Bio-Rad) and advanced bioprocessing tools (Danaher), which offer measurable advantages over legacy systems.

7. Strategic Realignments and Divestitures

Streamlining Portfolios: Companies like Enzo Biochem are divesting non-core divisions to focus on high-growth areas such as diagnostics and life sciences.

Acquisition Activity: Large players are leveraging acquisitions to strengthen their position in strategic growth markets like bioprocessing (Thermo Fisher and Danaher).

8. Optimism in Emerging Areas

High-growth Segments: Despite overall slowdown, certain segments like cell and gene therapy, liquid biopsy, and high-parameter flow cytometry are seeing growth as they align with industry trends toward precision medicine.

AI and Digitization: Providers are investing in AI-enabled solutions to enhance data insights, streamline workflows, and increase reproducibility in both research and clinical applications.

9. Long-term Outlook Remains Positive

Resilience of Biotech and Pharma: The sector remains crucial to healthcare innovation, and spending is expected to rebound once macroeconomic pressures ease.

Shifting Strategies: Vendors are adjusting to the current environment by focusing on value-driven products, expanding into clinical markets, and aligning with long-term industry shifts toward personalized medicine and efficiency.

Conclusion: 5 Tactics for Sales Teams

1. Strengthen Relationships
   Build trust by being a consultative resource. Regularly check in with clients to understand their evolving needs and position yourself as a partner, not just a vendor.

2. Focus on ROI
   Address cost concerns directly by emphasizing how your solutions deliver measurable efficiency, savings, or value. Tailor messaging to clients’ priorities. Business Case Template

3. Prioritize High-Value Accounts
   Use data to focus efforts on accounts with the greatest potential for growth or retention. Avoid wasting time on low-potential leads. Prioritize Growable Accounts

4. Stay Industry-Informed
   Understand trends and be an expert at what’s happening your customer’s world. Use this knowledge to engage clients with relevant insights. Deliver Expert Insights

5. Collaborate Internally
   Work closely with marketing and product teams to align on messaging and share client feedback. Ensure you’re equipped to handle objections and position solutions effectively.

Apple Podcast | Spotify | YouTube

Episode 52: [Sales] Adjusting your sales strategy based on personalities with Jason Mayr

• How to change your sales approach based on personalities

• Make the most out of the leads you get

• How to adapt to how your customer wants to communicate

• The biggest growth comes from getting out of your comfort zone

• Selling cutting edge tech vs established tech

1. Lead Generation: We’ll build target lists, write scientifically relevant messaging, and send messages on your behalf to book qualified sales meetings with biotech and pharma companies.

2. Succession for Reps: A skill development platform for life science sales reps who want to improve their sales skills, exceed their quota, and take the next step in their career.

3. Succession for Teams: If you want to upskill your team around prospecting, driving to close, key account management, AI, or any other topic, we can put together a training plan specific to your organization’s needs.

4. Strategy Call: Need more than training? Want help implementing and executing your sales strategy? In a 30-minute call, we will assess your company’s current situation and identify growth opportunities.

Special Offer: If you’ve made it this far, you can use the coupon code NEWSLETTER to get 20% off an individual Succession membership.

Recommended Products & Tools: We’ve used every one of these products and can highly recommend them to you. Everything from CRMs to AI tools.

Join SAMPS: A free community of sales and marketing professionals of the sciences. They run in-person events and put on regular webinars packed with great content.